2CBFly-NBOMe

2CBFly-NBOMe, also known as NBOMe-2C-B-FLY or as Cimbi-31, is a serotonin receptor modulator of the phenethylamine, DOx, and FLY families. It was indirectly derived from the phenethylamine hallucinogen 2C-B is and related to benzodifurans like 2C-B-FLY and N-benzylphenethylamines like 25B-NBOMe.

Interactions

Pharmacology

Pharmacodynamics

2CBFly-NBOMe acts as a potent partial agonist for the 5-HT_2A serotonin receptor subtype.

History

2CBFly-NBOMe was discovered in 2002, and further researched by Ralf Heim at the Free University of Berlin, and subsequently investigated in more detail by a team at Purdue University led by David E. Nichols.

Society and culture

Legal status

Canada

2CBFly-NBOMe is a controlled substance in Canada under phenethylamine blanket-ban language.

United Kingdom

United States

2CBFly-NBOMe is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.
2CBFly-NBOMe is a controlled substance in Vermont as of January 2016.